Thermoresponsive Iron Oxide Nanocubes for an Effective Clinical Translation of Magnetic Hyperthermia and Heat-Mediated Chemotherapy.
Animals
Cell Line, Tumor
Cell Survival
/ drug effects
Doxorubicin
/ chemistry
Drug Carriers
/ chemistry
Ferric Compounds
/ chemistry
Humans
Hyperthermia, Induced
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Magnetite Nanoparticles
/ chemistry
Mice
Mice, Nude
Nanostructures
/ chemistry
Neoplasms
/ diagnostic imaging
Polymers
/ chemistry
Tissue Distribution
Transplantation, Heterologous
Ultraviolet Rays
cancer therapy
combined chemotherapy
doxorubicin
drug delivery
magnetic hyperthermia
thermoresponsive polymer
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
13 Feb 2019
13 Feb 2019
Historique:
pubmed:
10
1
2019
medline:
1
6
2019
entrez:
10
1
2019
Statut:
ppublish
Résumé
The use of magnetic nanoparticles in oncothermia has been investigated for decades, but an effective combination of magnetic nanoparticles and localized chemotherapy under clinical magnetic hyperthermia (MH) conditions calls for novel platforms. In this study, we have engineered magnetic thermoresponsive iron oxide nanocubes (TR-cubes) to merge MH treatment with heat-mediated drug delivery, having in mind the clinical translation of the nanoplatform. We have chosen iron oxide based nanoparticles with a cubic shape because of their outstanding heat performance under MH clinical conditions, which makes them benchmark agents for MH. Accomplishing a surface-initiated polymerization of strongly interactive nanoparticles such as our iron oxide nanocubes, however, remains the main challenge to overcome. Here, we demonstrate that it is possible to accelerate the growth of a polymer shell on each nanocube by simple irradiation of a copper-mediated polymerization with a ultraviolet light (UV) light, which both speeds up the polymerization and prevents nanocube aggregation. Moreover, we demonstrate herein that these TR-cubes can carry chemotherapeutic doxorubicin (DOXO-loaded-TR-cubes) without compromising their thermoresponsiveness both in vitro and in vivo. In vivo efficacy studies showed complete tumor suppression and the highest survival rate for animals that had been treated with DOXO-loaded-TR-cubes, only when they were exposed to MH. The biodistribution of intravenously injected TR-cubes showed signs of renal clearance within 1 week and complete clearance after 5 months. This biomedical platform works under clinical MH conditions and at a low iron dosage, which will enable the translation of dual MH/heat-mediated chemotherapy, thus overcoming the clinical limitation of MH: i.e., being able to monitor tumor progression post-MH-treatment by magnetic resonance imaging (MRI).
Identifiants
pubmed: 30624889
doi: 10.1021/acsami.8b16226
pmc: PMC6376448
doi:
Substances chimiques
Drug Carriers
0
Ferric Compounds
0
Magnetite Nanoparticles
0
Polymers
0
ferric oxide
1K09F3G675
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5727-5739Références
Bioanalysis. 2011 Feb;3(3):333-44
pubmed: 21320053
Nat Mater. 2013 Nov;12(11):991-1003
pubmed: 24150417
Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14152-6
pubmed: 24255024
Langmuir. 2007 May 22;23(11):6342-51
pubmed: 17461602
Biotechnol J. 2011 Nov;6(11):1342-7
pubmed: 22069094
Ann Oncol. 2002 Aug;13(8):1173-84
pubmed: 12181239
Nat Mater. 2010 Feb;9(2):101-13
pubmed: 20094081
ACS Nano. 2011 Aug 23;5(8):6279-96
pubmed: 21732678
J Am Chem Soc. 2014 Jan 22;136(3):1141-9
pubmed: 24372509
Nanotechnology. 2011 Jul 1;22(26):265102
pubmed: 21576784
Lancet Oncol. 2010 Jun;11(6):561-70
pubmed: 20434400
ACS Appl Mater Interfaces. 2015 May 20;7(19):10132-45
pubmed: 25840122
ACS Macro Lett. 2014 Aug 19;3(8):732-737
pubmed: 35590690
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Chem Soc Rev. 2012 Jun 7;41(11):4306-34
pubmed: 22481569
J Am Chem Soc. 2010 Aug 11;132(31):10623-5
pubmed: 20681678
Pharmacol Ther. 1990;47(2):219-31
pubmed: 2203071
Int J Hyperthermia. 2008 Sep;24(6):467-74
pubmed: 18608593
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Int J Hyperthermia. 2011;27(5):491-502
pubmed: 21756046
Macromol Rapid Commun. 2015 Sep;36(18):1681-6
pubmed: 26149622
Lab Anim (NY). 2013 Jun;42(6):217-24
pubmed: 23689461
FASEB J. 1997 Oct;11(12):931-6
pubmed: 9337145
Chem Rev. 2017 Feb 8;117(3):1105-1318
pubmed: 28135076
Int J Hyperthermia. 2010;26(8):790-5
pubmed: 20653418
Int J Hyperthermia. 2013 Dec;29(8):828-34
pubmed: 24219800
Langmuir. 2015 Jan 20;31(2):808-16
pubmed: 25569814
Chem Rev. 2015 Sep 23;115(18):9745-800
pubmed: 26313922
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1252-1265
pubmed: 18558452
Sci Rep. 2018 Mar 20;8(1):4916
pubmed: 29559734
ACS Nano. 2012 Apr 24;6(4):3080-91
pubmed: 22494015
Chem Rev. 2015 Oct 14;115(19):10637-89
pubmed: 26250431
Electromagn Biol Med. 2009;28(2):148-65
pubmed: 19811397
Nanoscale. 2017 Apr 20;9(16):5094-5101
pubmed: 28397910
ACS Nano. 2014 May 27;8(5):4268-83
pubmed: 24738788
Methods Mol Biol. 2013;1025:137-55
pubmed: 23918335
J Am Chem Soc. 2017 Apr 26;139(16):5939-5945
pubmed: 28406296
Chem Rev. 2016 Sep 14;116(17):10167-211
pubmed: 26978484
Acc Chem Res. 2018 May 15;51(5):999-1013
pubmed: 29733199
Sci Rep. 2016 Jun 23;6:28539
pubmed: 27335342
J Biomed Mater Res. 1991 Dec;25(12):1547-62
pubmed: 1839026
J Mater Chem B. 2014 Jul 28;2(28):4426-4434
pubmed: 32261543
Nanomaterials (Basel). 2017 Mar 28;7(4):
pubmed: 28350351
J Natl Cancer Inst. 1989 May 3;81(9):696-701
pubmed: 2565403
Langmuir. 2008 Jan 1;24(1):239-44
pubmed: 18052081
Int J Hyperthermia. 2018 Dec;34(8):1316-1328
pubmed: 29353516
Int J Hyperthermia. 2016;32(1):4-13
pubmed: 26850697
Hum Reprod Update. 2001 Nov-Dec;7(6):535-43
pubmed: 11727861
Nanoscale. 2016 Jun 16;8(24):12152-61
pubmed: 26892588
ACS Appl Mater Interfaces. 2017 Aug 9;9(31):25775-25788
pubmed: 28723064
Nat Biotechnol. 2016 Apr;34(4):414-8
pubmed: 26974511
Int J Hyperthermia. 2005 Nov;21(7):637-47
pubmed: 16304715